Dare Bioscience, with the ticker DARE, is set to organize a live webinar on Wednesday, August 6, 2025, focusing on their innovative product, "DARE to PLAY." This event, held in partnership with The National Association of Nurse Practitioners in Women’s Health, will discuss a topical sildenafil cream created specifically for women. Utilizing the same active component found in Viagra, this formulation is clinically proven to enhance genital blood flow and improve sexual response in women.
The company highlights that "DARE to PLAY" distinguishes itself from other unproven products through its robust clinical backing, ensuring sildenafil is delivered effectively to the area where it can be most beneficial. This addresses a significant gap in women’s health by translating scientific research into practical solutions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Dare Bioscience Inc (DARE, Financial) is $13.00 with a high estimate of $14.00 and a low estimate of $12.00. The average target implies an upside of 415.87% from the current price of $2.52. More detailed estimate data can be found on the Dare Bioscience Inc (DARE) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Dare Bioscience Inc's (DARE, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
DARE Key Business Developments
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Dare Bioscience Inc (DARE, Financial) is expanding its product offerings with three new solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026.
- The company is leveraging a dual path strategy to commercialize its products via 503b compounding while continuing to seek FDA approval, accelerating market availability.
- Dare Bioscience Inc (DARE) is targeting the $4.5 billion compounded hormone therapy market, creating significant commercial opportunities.
- The company has reduced its general and administrative expenses by 14% and R&D expenses by 31% compared to Q1 2024, indicating effective cost management.
- Dare Bioscience Inc (DARE) is actively pursuing strategic partnerships and collaborations to enhance product accessibility across multiple channels.
Negative Points
- The company reported a comprehensive loss of approximately $4.4 million for the first quarter of 2025.
- Dare Bioscience Inc (DARE) has a working capital deficit of approximately $9.4 million, which may impact its financial flexibility.
- The company is still in the process of securing manufacturing capacity for its products, which may delay market entry.
- There is uncertainty regarding the enrollment rate for the pivotal phase 3 contraceptive efficacy study of Ovaprine.
- The company's dual path strategy may face challenges in balancing regulatory requirements and market demands.
